Solution
David answered on
Dec 31 2021
P a g e | 1
C A S E A N A L Y S I S : M E R C K , T H E F D A
A N D T H E V I O X X R E C A L L
P a g e | 2
INTRODUCTION
This is a case analysis report, prepared on Merck; a leading pharmaceutical company in terms
of profit. It is among the top five pharmaceutical companies in US, with strong research and
development framework that helps the company in launching innovative medicines that assist
in development of the society. Organization had a huge market reputation, as it was
continuously awarded by Fortune magazine for seven consecutive years as the most admired
organization. Merck was known in the market for its innovative product offerings and ethical
service delivery approach of doing business. However, from 2004, company saw a negative
turnaround phase that took a stable organization to a negative performance level with fall in
stock prices and profits of the company.
Vioxx a pain killer, regarded as a miracle drug invented by the company had negative impact
on the patient’s heart; for this reason, it has been recall in the year 2004, after 84 million
people have consumed it worldwide, out of which 55,000 died. After the recall of the drug
almost 6000 lawsuits have been charged on the company. This case analysis has been written
with objectives of analyzing the ethical position of the company, its strategies and
ecommended strategies for the same (Lawrence & Weber, 2010).
QUESTION 1
Do you believe Merck acted in a socially responsible and ethical manner in regard to
Vioxx? Why or why not? In your answer, please address the company’s drug
development and testing, marketing and advertising, relationship with government
egulators and policy market and handling of recall.
P a g e | 3
ANSWER
Before commenting on the ethical position of Merck, it is important to analyze its position,
strategies and actions. Therefore, here is a critical evaluation of different organizational
actions taken by the company, which are as follow;
DRUG DEVELOPMENT AND TESTING
Various surveys and analysis were taken during the drug development and testing phase,
which states that different analysis at the development phase shows that Vioxx will help in
locking the COX-2 enzyme that helps in controlling the pain in the stomach and also it
keeps the COX-1 beneficial enzyme at its place. However, according to the market research
eport in 1997, a Merck Scientist has written an email mentioning the ill impact that medicine
will have on the cardiovascular of the patient who intake it, but this email has been taken out
of context.
Similarly, according to the results of VIGOR study also the drug users had five times high
chances of heart attack then the consumer that uses other medicines which are available over
the counters.
MARKETING AND ADVERTISING
Another important aspect is the advertisement of medicines in the market, though the
company used many of the marketing tricks used by other pharmaceuticals companies; this
includes gifts to doctors, free meals, tickets etc. According to the given data in the year 2003,
the company spent around $422 million just to market Vioxx to doctors and different
hospitals. According to the information given in the Wall street Journal, on Merck name
Dodge Ball Vioxx, shows that how the company trained its employees and sales
epresentatives to avoid the questions regarding the concerns about the medicine.
P a g e | 4
Another important aspect occu
ed when FDA allowed direct to consumer marketing of
medicines, the company took advantage of this freedom and done huge expenditure of around
$ 500 million to advertise Vioxx in the market; it also launched TV commercials taking
Olympic figure skater, Dorothy Hamill and influence customer choice of medicine, which is
not ethical.
GOVERNMENT REGULATORS AND POLICY MARKET
Increasing involvement of political parties in influencing the decision of FDA has both
positive and negative impact on the decision taken by the management. The formation of
PAC, the non-profit organization that has the power to take unlimited donation without
disclosing the name of the contributor, was also used by Merck to provide soft money
contribution, as the company spent around $40.7 million between 1998 and 2004 on...